This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Colfax (CFX) Shares Gain 41% in 3 Months: What's Driving It?
by Zacks Equity Research
Colfax (CFX), with 41% growth in shares in the past three months, benefits from the overall revival in the broader market, buyout impacts, solid product offerings and cost-saving measures.
Can Colfax (CFX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Xylem (XYL) Provides Update on Q2 results, Confirms Deal Wins
by Zacks Equity Research
Xylem (XYL) provides a financial update for second-quarter results. Also, it secures two significant contracts in the second quarter.
Alcoa's (AA) Unit Closes $750M Worth Senior Notes Offering
by Zacks Equity Research
Alcoa's (AA) subsidiary closes the offering of $750 million worth of senior notes. The proceeds will be used for boosting its cash balance and satisfying corporate purposes.
Here's Why You Should Consider Buying Altra Industrial (AIMC)
by Zacks Equity Research
Altra Industrial (AIMC) gains from its solid product portfolio, strength across factory automation and medical end markets, robust liquidity position, and cost-management initiatives.
Enerpac's Products & Cost-Saving Moves to Aid Amid Pandemic
by Zacks Equity Research
Enerpac's (EPAC) efforts to introduce new products as well as its cost-savings actions are likely to aid, especially in the present uncertainties caused by the coronavirus outbreak.
Why Is Colfax (CFX) Up 22.4% Since Last Earnings Report?
by Zacks Equity Research
Colfax (CFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Colfax (CFX) Declines 23% YTD: What's Hurting the Stock?
by Zacks Equity Research
Colfax (CFX), with a 23% decline in shares so far in 2020, faces the adverse impacts of the pandemic. High debts and forex woes are other concerns. However, cost-reduction actions might aid.
Colfax (CFX) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Colfax's (CFX) Q1 results reflect the adverse impacts of the pandemic and contributions from the DJO Global buyout. It withdraws projections for 2020, while expects demand to be the lowest in the second quarter.
Colfax (CFX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Colfax (CFX) delivered earnings and revenue surprises of 2.70% and 3.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Industrial Stocks' May 7 Earnings Roster: BLL, AAXN & More
by Zacks Equity Research
A peak at how some industrials are expected to fare this earnings season amid the coronavirus impact.
Earnings Preview: Colfax (CFX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Colfax (CFX) Surges: Stock Moves 6.1% Higher
by Zacks Equity Research
Colfax (CFX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Colfax (CFX) Displays Bright Prospects, Headwinds Remain
by Zacks Equity Research
Colfax (CFX) is likely to benefit from its focus on strengthening segmental businesses, productivity actions and acquisitions. However, rising cost of sales and high debt remain concerns.
Is Colfax (CFX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Enersys Gains From Solid Demand & Buyouts Amid Cost Woes
by Zacks Equity Research
Enersys (ENS) benefits from strength in its transportation business, solid demand for NexSys TPPL products and buyout of Alpha Technologies. However, rising cost of sales and high debt remain concerns.
Colfax (CFX) Down 55.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Colfax (CFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kennametal (KMT) Declines 39% YTD: What's Hurting the Stock?
by Zacks Equity Research
Kennametal (KMT), with a 39% decline in shares so far in 2020, faces headwinds from difficult end-market conditions, issues with 737 MAX and higher taxes.
Should Value Investors Pick Colfax (CFX) Stock Right Now?
by Zacks Equity Research
Is Colfax (CFX) a great pick from the value investor's perspective right now? Read on to know more.
4 Reasons Why You Should Avoid IDEX (IEX) Stock for Now
by Zacks Equity Research
IDEX (IEX) is exposed to challenging end markets, unfavorable movements in foreign currencies, and the impacts of variable compensation, tax rate and growth investments.
Colfax to Gain From Solid Product Lines & Buyouts Amid Risks
by Zacks Equity Research
Colfax (CFX) is likely to benefit from its focus on strengthening segmental businesses and productivity actions, and gains from acquired assets. Cost of sales witnesses a rise.
Colfax (CFX) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Colfax's (CFX) fourth-quarter 2019 results benefit from growth in existing businesses and acquired assets despite forex woes.
Earnings Preview: Colfax (CFX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Colfax (CFX) Benefits From Acquired Assets Despite Costs Woes
by Zacks Equity Research
Colfax (CFX) is likely to gain from acquired assets, healthy medical technology business and emerging market exposure. High costs, forex woes and huge debts are concerns.
Colfax's (CFX) Shares Rally 33.4% in 6 Months: Here's Why
by Zacks Equity Research
Colfax (CFX) benefits from acquisitions, productivity actions and product developments. However, escalating costs and a highly leveraged balance sheet are headwinds.